For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Transkaryotic Therapies, Inc.

Calculating rank

USPTO Granted Patents = 40

% Expired Patents = 2.5

Trademarks = 1

Forward Citations = 1,240

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Douglas A Treco (31 out of 61 patents)

Richard F Selden (28 out of 30 patents)

Michael W Heartlein (26 out of 189 patents)

4. Carol M Kinoshita (5 out of 6 patents)

5. Marianne Borowski (5 out of 11 patents)

6. Melanie D Williams (5 out of 5 patents)

7. Michael F Concino (4 out of 27 patents)

8. Frances P Gillispie (4 out of 4 patents)

9. Jeffrey F Lemontt (4 out of 7 patents)

10. Rochelle Mineau-Hanschke (4 out of 4 patents)

11. Allan M Miller (4 out of 4 patents)

12. Peter Francis Daniel (1 out of 5 patents)

13. Evguenii Ivanov (1 out of 1 patent)

14. Thomas J Schuetz (1 out of 1 patent)

15. Brian M Hauge (1 out of 1 patent)

Core Competencies:

Chimeric Polypeptide

Messenger RNA

Gene Therapy

Protein Delivery

Erythropoietin

Insulinotropin

Homologous Recombination

Hybrid Matrix Implants

Targeted DNA Introduction

Clonal Cell Strains

Genomic Sequences

Transport Proteins

40 patents: Sort by Forward Citations

1. 7122354 - Nucleic acid encoding a chimeric polypeptide (2006-10-17),

2. 6924365 - Optimized messenger RNA (2005-08-02),

3. 6858578 - Chimeric proteins for use in transport of a selected substance into cells (2005-02-22),

4. 6846676 - In Vivo production and delivery of erythropoietin or insulinotropin for gene therapy (2005-01-25),

5. 6692737 - In vivo protein production and delivery system for gene therapy (2004-02-17),

6. 6670178 - In Vivo production and delivery of insulinotropin for gene therapy (2003-12-30),

7. 6582391 - Hybrid matrix implants and explants (2003-06-24),

8. 6569681 - Methods of improving homologous recombination (2003-05-27),

9. 6566099 - Nucleic acid encoding a chimeric polypeptide (2003-05-20),

10. 6565844 - Protein production and protein delivery (2003-05-20),

11. 6537542 - Targeted introduction of DNA into primary or secondary cells and their use for gene therapy and protein production (2003-03-25),

12. 6531124 - In vivo production and delivery of insulinotropin for gene therapy (2003-03-11),

13. 6472181 - Hybrid matrix implants and explants (2002-10-29),

14. 6458574 - Treatment of a &agr;-galactosidase a deficiency (2002-10-01),

15. 6419920 - Hybrid matrix implants and explants (2002-07-16),

Company Overview

Transkaryotic Therapies, Inc., based in Cambridge, MA, specializes in innovative biopharmaceutical solutions, focusing on gene therapy and advanced protein delivery systems. The company is known for its work with chimeric polypeptides and messenger RNA technologies, aiming to develop therapies that enhance the efficacy of treatments for various conditions. Their research encompasses critical areas such as erythropoietin and insulinotropin, leveraging homologous recombination and hybrid matrix implants to improve therapeutic outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

40 Patents

#71 in Cambridge, MA

#496 in Massachusetts

#8,637 in US

#17,098 in the World

Cambridge, MA, United States of America

Transkaryotic Therapies, Inc.

Forward Citations = 1,240

15 inventors:

Douglas A Treco (31 out of 61 patents)

Richard F Selden (28 out of 30 patents)

Michael W Heartlein (26 out of 189 patents)

4. Carol M Kinoshita (5 out of 6 patents)

5. Marianne Borowski (5 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Transkaryotic Therapies, Inc.. Retrieved from https://idiyas.com/company/transkaryotic-therapies

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…